Cetera Investment Advisers Buys 1,336 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Cetera Investment Advisers increased its stake in Regeneron Pharmaceuticals by 14.5%, now owning 10,575 shares worth approximately $6.7 million.
• The company's recent earnings report revealed a miss on earnings per share at $8.22 compared to an estimate of $8.83, alongside a 3.7% year-over-year revenue decline.
• Regeneron's stock is currently rated as a Moderate Buy by analysts, with an average price target of $837.61 amidst recent rating changes from various investment firms.

Cetera Investment Advisers boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 14.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,575 shares of the biopharmaceutical company's stock after buying an additional 1,336 shares during the quarter. Cetera Investment Advisers' holdings in Regeneron Pharmaceuticals were worth $6,707,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Marietta Wealth Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 30.2% during the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock worth $6,836,000 after purchasing an additional 2,501 shares during the last quarter. Pamalican Asset Management Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $4,915,000. Rhenman & Partners Asset Management AB grew its holdings in shares of Regeneron Pharmaceuticals by 11.4% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after buying an additional 4,457 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after buying an additional 814,713 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Regeneron Pharmaceuticals by 3.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock worth $16,255,000 after buying an additional 955 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Guggenheim raised their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. The Goldman Sachs Group lowered their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Bank of America lowered their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a report on Thursday, April 17th. Finally, Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $841.30.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded down $16.58 during trading on Wednesday, hitting $553.32. 486,381 shares of the company's stock traded hands, compared to its average volume of 1,116,328. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 4.73. The firm's fifty day moving average price is $537.05 and its 200 day moving average price is $601.77. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The company has a market cap of $59.74 billion, a PE ratio of 13.93, a PEG ratio of 2.14 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm's revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the business earned $11.56 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be given a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.